The Tariff Trap: How Trump’s Proposal Could Devastate India’s Pharmaceutical Industry

The phrase “pharmacy of the world” has become synonymous with India, a nod to its long-standing reputation as a hub for affordable generic medicines. But beneath the surface, India’s pharmaceutical industry is on shaky ground, and the latest salvo from the US could be its undoing.

Donald Trump’s proposed tariffs on generic medicines are being touted as a major push to bring more drug manufacturing back to American shores. This move has far-reaching consequences for India, where generic drugs account for 90% of prescriptions filled in the US alone. The Indian pharmaceutical industry generates nearly $11 billion in sales from the US market each year.

The proposed tariffs would impose a 100% tax on generic medicines from August 2028 and increase it to 200% after one year. Analysts warn that such steep tariffs will disrupt supply chains, making it increasingly difficult for Indian pharmaceutical companies to export their products to the US. Vivek Mishra, deputy director of the Strategic Studies Programme at the Observer Research Foundation, notes that this could lead to a fundamental shift in the way Indian companies operate – with many forced to set up bases in the US.

India’s reliance on the US market has been a double-edged sword. While it has fueled the growth of the industry, it also makes companies vulnerable to fluctuations in global trade policies. This irony is not lost on those who have watched India’s pharmaceutical industry grow over the years. With such a significant chunk of its revenues coming from the US, Indian companies haven’t diversified their portfolios as aggressively as they could.

The scenario echoes the controversy surrounding tariffs imposed by Trump on Chinese goods just a few years ago. In both cases, the US is attempting to level the playing field by targeting countries with which it has significant trade imbalances. While this move may gain short-term political capital for Trump, its long-term implications are far from clear.

India’s pharmaceutical industry will need to adapt quickly to survive this tariff trap. Companies like Cipla and Lupin, two of the biggest players in the US market, will have to scramble to find new markets or develop their own manufacturing capabilities within the US. This is a daunting task that requires significant investment and strategic planning – areas where Indian companies are often criticized for falling short.

The consequences of this tariff trap extend beyond India’s pharmaceutical industry. Generic medicines have been a lifeline for many low-income countries, providing them with essential treatments at prices they can afford. If the US tariffs go ahead, these countries may find themselves caught in the crossfire – forced to pay higher prices or do without life-saving medications.

The implications of Trump’s proposed tariffs are far-reaching and complex, involving global health and trade policies. As this drama unfolds, it’s essential to keep an eye on how other countries respond to the US move. Will they follow suit, imposing similar restrictions on generic medicines? Or will some brave new path be forged – one that prioritizes access to affordable healthcare over protectionist interests?

India’s pharmaceutical industry has reached a critical juncture. It must adapt quickly and strategically to survive this tariff trap – or risk losing its status as “pharmacy of the world” forever.